Jason R. Westin, MD, MS, FACP

Dr. Graff reviews the EPCORE DLBCL-1 Phase 3 trial comparing epcoritamab monotherapy against investigator's choice of R-GemOx or bendamustine-rituximab in relapsed/refractory DLBCL.

Dr. Johnson addresses whether using CD19-directed agents in the frontline compromises subsequent relapse options.

Dr. Graff discusses the challenging scenario of a positive interim PET scan mid-treatment.

Dr. Johnson confirms dose-adjusted R-EPOCH as his standard for the vast majority of double-hit patients outside clinical trials, noting POLARIX and frontMIND each included only approximately 6% to 8% double-hit patients, far too few for meaningful subgroup analysis.

Dr. Graff addresses whether the absence of overall survival benefit from either POLARIX or frontMIND should discourage adoption.

Dr. Lunning discusses decision-making when both Pola-R-CHP and Tafa-Len-R-CHOP are options.

Experts review new Phase 3 DLBCL data, Pola-R-CHP adoption, biomarker testing, and emerging molecular risk groups as bispecific antibodies reshape relapsed care.

Experts review new Phase 3 DLBCL data, Pola-R-CHP adoption, biomarker testing, and emerging molecular risk groups as bispecific antibodies reshape relapsed care.

Jason R. Westin, MD, MS, FACP, reviews the background and study design of ZUMA-23, the first Phase III, randomized controlled study to evaluate CAR T-cell therapy as a first-line regimen in patients with high-risk LBCL.